17075109

Source:http://linkedlifedata.com/resource/pubmed/id/17075109

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0021149, umls-concept:C0030705, umls-concept:C0036525, umls-concept:C0332293, umls-concept:C0392756, umls-concept:C0677829, umls-concept:C1522484, umls-concept:C1527249, umls-concept:C1568868
pubmed:issue	33
pubmed:dateCreated	2006-11-20
pubmed:abstractText	To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/17075109-17075108, http://linkedlifedata.com/resource/pubmed/commentcorrection/17075109-17602066
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Fibroblast Growth Factor 7, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1527-7755
pubmed:author	pubmed-author:AbdiEhteshamE, pubmed-author:CesanoAlessandraA, pubmed-author:ChenMon-GyMG, pubmed-author:ClarkeStephenS, pubmed-author:DavisIan DID, pubmed-author:GaykoUrteU, pubmed-author:GutheilJohnJ, pubmed-author:RosenLee SLS, pubmed-author:SchnellFrederick MFM, pubmed-author:ZalcbergJohnJ
pubmed:issnType	Electronic
pubmed:day	20
pubmed:volume	24
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	5194-200
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:17075109-Aged, pubmed-meshheading:17075109-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17075109-Colorectal Neoplasms, pubmed-meshheading:17075109-Diarrhea, pubmed-meshheading:17075109-Drug Administration Schedule, pubmed-meshheading:17075109-Female, pubmed-meshheading:17075109-Fibroblast Growth Factor 7, pubmed-meshheading:17075109-Fluorouracil, pubmed-meshheading:17075109-Humans, pubmed-meshheading:17075109-Incidence, pubmed-meshheading:17075109-Kaplan-Meier Estimate, pubmed-meshheading:17075109-Leucovorin, pubmed-meshheading:17075109-Male, pubmed-meshheading:17075109-Middle Aged, pubmed-meshheading:17075109-Mouth Mucosa, pubmed-meshheading:17075109-Questionnaires, pubmed-meshheading:17075109-Severity of Illness Index, pubmed-meshheading:17075109-Stomatitis, pubmed-meshheading:17075109-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
pubmed:affiliation	Premiere Oncology, John Wayne Cancer Institute, St John's Health Center, Santa Monica, CA 90404, USA. lrosen@premiereoncology.com
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I